Bulletin
Investor Alert

Bayer AG ADR

OTC: BAYRY

GO
/marketstate/country/us

Market closed

 --Quotes are delayed by 20 min

Dec 1, 2020, 3:59 p.m.

/zigman2/quotes/203424967/delayed

$

14.82

Change

+0.30 +2.04%

Volume

Volume 752,728

Quotes are delayed by 20 min

/zigman2/quotes/203424967/delayed

Previous close

$ 14.52

$ 14.82

Change

+0.30 +2.04%

Day low

Day high

$14.67

$14.82

Open

52 week low

52 week high

$11.75

$21.49

Open

Company Description

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in...

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Valuation

P/E Current

11.58

P/E Ratio (without extraordinary items)

17.47

Price to Sales Ratio

1.64

Price to Book Ratio

1.51

Price to Cash Flow Ratio

10.41

Enterprise Value to EBITDA

11.75

Enterprise Value to Sales

2.42

Total Debt to Enterprise Value

0.37

Efficiency

Revenue/Employee

419,412.00

Income Per Employee

23,222.00

Receivables Turnover

3.09

Total Asset Turnover

0.33

Liquidity

Current Ratio

1.37

Quick Ratio

0.90

Cash Ratio

0.23

Profitability

Gross Margin

59.89

Operating Margin

10.38

Pretax Margin

6.25

Net Margin

5.54

Return on Assets

1.84

Return on Equity

5.17

Return on Total Capital

5.20

Return on Invested Capital

2.87

Capital Structure

Total Debt to Total Equity

82.33

Total Debt to Total Capital

45.15

Total Debt to Total Assets

29.67

Long-Term Debt to Equity

77.97

Long-Term Debt to Total Capital

42.77

Officers and Executives

Name Age Officer Since Title
Dr. Norbert Winkeljohann 62 2018 Member-Supervisory Board
Mr. Werner Baumann 57 1988 Principal
Mr. Wolfgang U. Nickl 50 2018 Member-Management Board
Mr. Bijoy Sagar 50 2020 Chief Information Technology Officer
Ms. Marianne de Backer 50 2019 Head-Licensing Pharmaceuticals Division

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/bayry

MarketWatch News on BAYRY

  1. Stocks Close Higher on Stimulus Hopes, Manufacturing Data

    48 min ago

    - Barron's Online

  2. Bayer to raise $1.65B through Elanco share sale

    2:18 a.m. Today

    - MarketWatch.com

  3. Elanco Animal Health Stock Stumbles After Earnings Report

    1:42 p.m. Nov. 6, 2020

    - Barron's Online

  4. Bayer backs 2020 outlook, but posts loss

    2:04 a.m. Nov. 3, 2020

    - MarketWatch.com

  5. George Floyd’s Death Leads to a Surge of New Black Board Members

    8:31 p.m. Oct. 30, 2020

    - Barron's Online

  6. Bayer Is Betting on Gene Therapy With a $4 Billion U.S. Acquisition

    10:37 a.m. Oct. 26, 2020

    - Barron's Online

  7. Bayer to pay up to $4 billion for Asklepios Bio

    2:43 a.m. Oct. 26, 2020

    - MarketWatch.com

  8. Bayer late lymphoma study meets primary endpoint

    2:07 a.m. Oct. 14, 2020

    - MarketWatch.com

  9. Stocks Close Up Slightly as Stimulus Talks Falter

    3:13 p.m. Oct. 1, 2020

    - Barron's Online

  10. Bayer unveils billions in new cost cuts

    7:21 p.m. Sept. 30, 2020

    - MarketWatch.com

  11. Bayer extends CEO's contract

    12:37 a.m. Sept. 11, 2020

    - MarketWatch.com

  12. Dow Turns Positive for the Year as the Dollar Falls

    3:41 p.m. Aug. 28, 2020

    - Barron's Online

  13. The Dow Is Up Because Consumers Are Still Spending

    11:46 a.m. Aug. 28, 2020

    - Barron's Online

  14. Bayer: Prostate cancer drug approved in China

    2:57 a.m. Aug. 27, 2020

    - MarketWatch.com

  15. Why Dell Stock Can Gain 42%: Portfolio Manager

    8:56 a.m. Aug. 21, 2020

    - Barron's Online

  16. Loading more headlines...
/news/nonmarketwatch/company/us/bayry

Other News on BAYRY

  1. IPO Update: Sigilon Therapeutics Aims For $101 Million IPO

    4:45 p.m. Today

    - Seeking Alpha

  2. Judge tosses Bayer's $650M PCB pollution settlement

    12:56 p.m. Nov. 30, 2020

    - Seeking Alpha

  3. Wide-Moat Stocks On Sale - The December 2020 Heat Map

    1:45 p.m. Nov. 29, 2020

    - Seeking Alpha

  4. Sigilon Therapeutics Starts U.S. IPO Plan

    1:24 p.m. Nov. 19, 2020

    - Seeking Alpha

  5. European advisory group backs new uses of six medicines

    8:42 a.m. Nov. 13, 2020

    - Seeking Alpha

  6. Compugen: Speculative Play For Immuno-Oncology Exposure

    9:59 a.m. Nov. 7, 2020

    - Seeking Alpha

  7. Regeneron's (REGN) Q3 Earnings & Sales Surpass Estimates

    12:55 p.m. Nov. 5, 2020

    - Zacks.com

  8. Rising Farm Exports to China Lift Agribusiness, Farmers

    9:00 a.m. Nov. 3, 2020

    - Jacob Bunge

  9. Loading more headlines...

At a Glance

Bayer AG

Kaiser-Wilhelm-Allee 1

Leverkusen, Nordrhein-Westfalen 51368

Phone

49 214301

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2020

Revenue

$43.55B

Net Income

$2.41B

2019 Sales Growth

10.0%

Employees

103,824

/news/pressrelease/company/us/bayry

Press Releases on BAYRY

  1. Biopesticides Market Projected to Garner Significant Revenues by 2025

    9 min ago

    - ABNewswire

  2. Global Specialty Chemicals Market Size, Share, Trends & Indstry Report to 2026

    12:38 p.m. Today

    - Heraldkeepers

  3. Diabetes Devices Market Size, Share to Grow Tremendously During 2020-2025 - Industry News

    7:44 a.m. Today

    - Market Insight Reports

  4. US Specialty Chemicals Market Share, Trends, Size, Research and Forecast 2020-2026

    3:52 a.m. Today

    - Heraldkeepers

  5. Loading more headlines...
Link to MarketWatch's Slice.